Background: Stage III ovarian cancer (OC) remains an important cause of cancer related mortality in women. After successful initial treatment, most patients eventually develop recurrent peritoneal disease which can only arise from peritoneal minimal residual disease (pMRD) left after primary cytoreductive surgery (CRS). Intesification of locoregional therapy through intraoperative intraperitoneal chemoperfusion (IPC) immediately following CRS may prevent or delay peritoneal recurrence. Although IPC, usually under hyperthermic conditions, is increasingly used in OC, its pharmacodynamic efficacy and the potential benefit of hyperthermia are at present unknown.
Aims: to study in a randomized Phase II trial the pharmacokinetics, pharmacodynamic properties, side effects, and efficacy of IPC with cisplatin in patients undergoing CRS for stage III epthelial OC.